Dr. Quigley is an Assoicate Professor of Hematology and Oncology and a physician-scientist engaged in translational investigation of acute leukemias (AML/ALL)at the University of Illinois at Chicago College of Medicine. His research is focused on leukemia and methods for cell metabolism to kill cancer cells. Dr. QuigleyGÇÖs effort is divided into 30% protected time for laboratory-based research, 50% effort devoted to care of patients with hematological malignancies (primarily leukemias), including HSCT patients and to teaching fellows, residents, and students, and 20% effort to administrative responsibilities including serving as Director of the Leukemia clinic, Chair of the University of Illinois Cancer Center Scientific (protocol) Review committee, co-chair of the UIC Medical Center Anti-Coagulation QI committee, and as the institutional PI for UIC clinical trials for The Alliance for Clinical Trials In Oncology Foundation.
Research in their laboratory has primarily been related to the role of the human cell-surface heme transporter (FLVCR) in erythropoiesis, focusing on the function of FLVCR, a retroviral receptor whose dysfunction impairs erythropoiesis in cats, causing a severe anemia. In recognition of their developing expertise in the area of heme biology, he published invited reviews of heme biology and transport in 2011, and reviews of the FLVCR and other heme transporters in 2013, 2014.
Dr. Quigley is the principal author on a chapter on Erythropoiesis in the 13th and forthcoming (14th ) edition of the most widely read hematology textbook, WintrobeGÇÖs Clinical Hematology (with Dr. Robert Means and Bertie Glader). This year he was invited to join the Porphyrias Consortium [Consortium of the Rare Disease Clinical Research Network (RDCRN) that focuses on the inborn errors of heme biosynthesis, the porphyrias]. He recently established a Porphyria clinic at UIC that serves the Mid-West region.
His research is focused on leukemia and methods for cell metabolism to kill cancer cells.